Drug Abuse Resistance Education , or D.A.R.E. , is an American education program that tries to prevent use of controlled drugs, membership in gangs, and violent behavior. It was founded in Los Angeles in 1983 as a joint initiative of then-LAPD chief Daryl Gates and the Los Angeles Unified ...
What's Extra Help? ; "Extra Help" is a Medicare program to help people with limited income and resources pay Medicare drug coverage (Part D) premiums, deductibles, coinsurance, and other costs. What's a premium, deductible, coinsurance, or copayment? · You also won't have to pay a Part D late enrollment penalty while you get Extra Help. What's the Part D penalty? · Some people qualify for Extra Help automatically, and other people have to apply. You'll get Extra Help automatically if you get: ...
Supporting the development and evaluation of new treatments for rare diseases is a key priority for the FDA. The FDA has authority to grant orphan drug designation to a drug or biological product to prevent, diagnose or treat a rare disease or condition. Orphan drug designation qualifies sponsors for incentives including: Sponsors seeking orphan drug designation for a drug must submit a request for designation to the agency. Sponsors requesting designation of the same drug for the same rare disease or condition as a previously designated produc ...
Monthly and quarterly metrics of the FDA Generic Drugs Program.
Search ; Namespaces · Page · Discussion ; Views · Read · Edit · View history
340B Program Compliance ; In January 2024, HRSA created a new webpage to provide in one place the resources available to covered entities regarding HRSA audits to ensure compliance with 340B Program requirements. As HRSA noted on the webpage, HRSA Patient Definition Guidelines (PDF - 31 KB), published 25 years ago, contain HRSA’s interpretation of key statutory requirements and continue to guide HRSA’s audit activities . In the coming weeks and months, HRSA will be sending a series of audit findings to covered entities where we have identif ...
Prior Drug Safety Priorities Reports ; Drug Safety Priorities 2022 (PDF - 4 MB) ; Drug Safety Priorities 2021 (PDF - 10 MB) ; Drug Safety Priorities 2020 (PDF - 7 MB) ; Drug Safety Priorities 2019 (PDF - 908 KB)
Program No., Compliance Program Title ; 7348.001, In Vivo Bioequivalence (PDF - 77KB) [ HTML version ] ; 7348.809A, Radioactive Drug Research Committee (PDF - 142KB) ; 7346.832, Preapproval Inspections (PDF - 700KB)
Français The Newfoundland and Labrador Prescription Drug Program (NLPDP) provides financial assistance for the purchase of eligible prescription medications for...
Plan for Medicare · Sign up for Medicare · Request to lower IRMAA · Apply for Part D Extra Help · Manage Medicare benefits